Vimarsana
Biggest News Aggregation in the World

Page 2 - Nasdaq Dmac News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Dmac. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Dmac Today - Breaking & Trending Today

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Director Purchases $254,150.00 in Stock - Vimarsana News

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Director Purchases $254,150.00 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) Director Randall Michael Giuffre acquired 65,000 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were bought at an average price of $3.91 per share, with a total value of $254,150.00. Following the transaction, the director now directly owns 360,355 shares […]

Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider Buys 38,364 Shares of Stock - Vimarsana News

Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider Buys 38,364 Shares of Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 38,364 shares of the stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $3.91 per share, with a total value of $150,003.24. Following the acquisition, the insider now owns 507,114 shares of the company’s stock, […]

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Oppenheimer - Vimarsana News

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Oppenheimer

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]

Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Drops By 5.6% - Vimarsana News

Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Drops By 5.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totalling 91,900 shares, a drop of 5.6% from the April 15th total of 97,400 shares. Based on an average daily trading volume, of 27,100 shares, the days-to-cover ratio […]

Head-To-Head Analysis: Marinus Pharmaceuticals (NASDAQ:MRNS) & DiaMedica Therapeutics (NASDAQ:DMAC) - Vimarsana News

Head-To-Head Analysis: Marinus Pharmaceuticals (NASDAQ:MRNS) & DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) and Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation. Volatility and Risk DiaMedica Therapeutics has a beta of […]